Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Kais Aldabbagh Ste´phane Pouderoux Lise Roca Sylvain Poujol Michel Fabbro Gilles Romieu William Jacot
- چاپ و سال / کشور: 2010
Description
Background Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM). We report in this study a retrospective analysis of the activity and safety of the VMM combination. Methods Patients were treated with a combination of VP-16 (100 mg/m2 on day 1), mitomycin C (MMC, 10 mg/m2 on day 1), and methotrexate (MTX, 12.5 mg/m2 twice a day on day 2 and 3) in a 21-day cycle. Results Seventy-five patients were treated. Median age was 48 years. A total of 256 cycles were administered. Median relative dose intensities were 0.87, 0.87, and 0.95 for VP-16, MMC, and MTX, respectively. Objective response rate was 31%, with a clinical benefit rate of 47%. Median response duration was 5.8 months. Median disease stabilization duration was 9.1 months. Median progressionfree survival (PFS) was 4.2 months with a 14% 1-year PFS rate. Median overall survival (OS) was 6.2 months, with a 25% 1-year OS rate. Myelosuppression was the most common toxicity. The most commonly reported extrahematological adverse event (AE) was fatigue. Emesis and alopecia were rarely reported. Conclusions This combination appears to be effective and well tolerated in this heavily pretreated metastatic breast cancer population.
Breast Cancer DOI 10.1007/s12282-010-0240-7 Received: 8 July 2010 / Accepted: 20 October 2010 The Japanese Breast Cancer Society 2010
